GS3-05: Evaluation of the Sensitivity to Endocrine Therapy (SETER/PR) assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial Author: Eleftherios P Mamounas, AdventHealth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback